60 65 70 75 80 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg APEX KSI-101 in MESI – Meaningful vision gains are rapidly achieved as early as Week 4 and ≥half of patients in the top two dose levels achieved a ≥15 letter gain 8 The APEX study is ongoing. Final results may be different due to data cleaning. Includes patients in the per protocol set that completed the Week 12 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Mean ETDRS Letters Observed BCVA over time Sample Size Weeks 2.5 mg 13 13 13 13 13 5 mg 13 13 13 13 13 10 mg 13 13 13 13 13 Proportion of ≥15 letter gainers Patients, % +10.7 +12.1 +8.8 31 62 54 49 0 20 40 60 80 100 2.5 mg (n=13) 5 mg (n=13) 10 mg (n=13) All patients (n=39) Mean Change Dose Level Preliminary analysis: all patients have completed Week 12